2022-11-11T11:33:38-06:00 2021-12-31 135565207 KPMG LLP 345 PARK AVENUE NEW YORK NY 101540102 990 2021-01-01 800631734 NEW YORK GENOME CENTER INC NEWY 6469777000 101 AVENUE OF THE AMERICAS 7TH FL NEW YORK NY 10013 MARIA JOANTA CHIEF FINANCIAL OFFICER 6469777000 2022-11-10 1 MARIA JOANTA 999009999 OSE JOSEPH-ERAMEH P02534927 2127589700 2022-11-09 3 AAL1 IAL1 2021 2022-09-23 18:48:47Z TOM MANIATIS 101 AVE OF THE AMERICAS NEW YORK NY 10013 75770198 0 X WWW.NYGENOME.ORG X 2010 DE ADVANCING GENOMIC RESEARCH TO DRIVE NOVEL BIOMEDICAL DISCOVERIES TO IMPROVE HUMAN HEALTH. 23 22 226 22 1994450 0 51639109 61556925 8497659 9002608 90496 27107 556725 1712471 60783989 72299111 1010263 1760070 0 0 28728885 27400508 2325 250 453549 42564807 39947593 72306280 69108421 -11522291 3190690 83547232 85222125 47595266 46079469 35951966 39142656 X OPERATE A STATE-OF-THE-ART, WORLD CLASS GENOMIC RESEARCH CENTER THAT CREATES AND USES ADVANCED GENOMICS TO UNDERSTAND THE GENETIC BASIS OF DISEASE. FOR MORE INFORMATION, SEE SCHEDULE O. 0 0 51412857 1760070 7531190 RESEARCH AND RESEARCH SEQUENCING: NYGC'S RESEARCH SCIENTISTS AND FACULTY CONDUCT RESEARCH INTO THE GENETIC FACTORS THAT CONTRIBUTE TO HUMAN DISEASE, BOTH IN THEIR OWN PROJECTS AND THROUGH COLLABORATIONS. NYGC RESEARCHERS HAVE PROJECTS UNDERWAY IN CANCER, INCLUDING LUNG, LIVER, BREAST AND MELANOMA, A MULTISITE VERY RARE CANCER PROJECT AND A LARGE COLLABORATIVE PROJECT STUDYING CANCER IN UNDERSERVED POPULATIONS IN NYC; NEURODEGENERATIVE DISEASES, INCLUDING ALS AND DEMENTIA AND NEUROPSYCHIATRIC DISEASES, FOCUSING ON AUTISM, AMONG OTHERS. IN 2021, NYGC SEQUENCED OVER 4,500 WHOLE GENOME SAMPLES, AS WELL AS NEARLY 6,000 COVID VIRAL SAMPLES, COMPLETED 611 PROJECTS, AND COLLABORATED WITH 101 INVESTIGATORS FROM 52 INSTITUTIONS WORLDWIDE. FOR MORE INFORMATION SEE SCHEDULE O. 4420664 1471418 CLINICAL SEQUENCING: NYGC IS AUTHORIZED BY THE NEW YORK STATE DEPARTMENT OF HEALTH TO OFFER THE FOLLOWING APPROVED CLINICAL TESTS THROUGH ITS CLEP/CLIA CERTIFIED CLINICAL LABORATORY: CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR UNDIAGNOSED DISEASE, CONSTITUTIONAL WHOLEGENOME SEQUENCING FOR PREDISPOSITIONAL GENETIC SCREENING, ONCOLOGY WHOLE GENOME AND TRANSCRIPTOME SEQUENCING, CONSTITUTIONAL WHOLE EXOME SEQUENCING, TARGETED VARIANT TESTING USING SANGER SEQUENCING, ONCOLOGY WHOLE EXOME AND TRANSCRIPTOME SEQUENCING, AND THE SMASH GENOMIC ASSAY. 55833521 1 1 0 1 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 1 1 1 1 0 0 0 0 1 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 57 0 1 226 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 23 22 0 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AR CA CO CT FL GA HI IL KS KY LA ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X NANCY KONG 6469777154 101 AVENUE OF THE AMERICAS 7TH FL NEW YORK NY 10013 X CHERYL A MOORE PRESIDENT & COO (THROUGH 3/21) 40.00 X X 628607 0 18267 TOM MANIATIS PHD SCIENTIFIC DIRECTOR & CEO 40.00 X X 616411 0 0 DAFNA BAR-SAGI PHD DIRECTOR 1.00 X 0 0 0 RUSSELL L CARSON MBA DIRECTOR & CO-CHAIR 4.00 X X 0 0 0 ELI CASDIN DIRECTOR 1.00 X 0 0 0 DENNIS S CHARNEY MD DIRECTOR 1.00 X 0 0 0 AUGUSTINE MK CHOI MD DIRECTOR 1.00 X 0 0 0 KENNETH A DILL PHD DIRECTOR (AS OF 6/21) 1.00 X 0 0 0 NICHOLAS DONOFRIO DIRECTOR 1.00 X 0 0 0 JOSEPH E EDELMAN DIRECTOR (AS OF 6/21) 1.00 X 0 0 0 JOHN B EHRENKRANZ DIRECTOR 1.00 X 0 0 0 ANTHONY B EVNIN PHD DIRECTOR 1.00 X 0 0 0 JOHN P HAVENS DIRECTOR (AS OF 11/21) 1.00 X 0 0 0 WESLIE R JANEWAY DIRECTOR 1.00 X 0 0 0 KENNETH KAUSHANSKY MD DIRECTOR (THROUGH 1/21) 1.00 X 0 0 0 RICHARD P LIFTON MD PHD DIRECTOR 1.00 X 0 0 0 EDISON T LIU MD DIRECTOR (THROUGH 2/21) 1.00 X 0 0 0 HERB PARDES MD DIRECTOR & VICE CHAIR 1.00 X 0 0 0 ANIL RUSTGI MD DIRECTOR (AS OF 2/21) 1.00 X 0 0 0 IVAN G SEIDENBERG MBA DIRECTOR & CO-CHAIR 4.00 X X 0 0 0 FRANK V SICA DIRECTOR & COMMITTEE CHAIR 1.00 X 0 0 0 JIM SIMONS PHD DIRECTOR 1.00 X 0 0 0 BRUCE STILLMAN PHD DIRECTOR 1.00 X 0 0 0 CRAIG B THOMPSON MD DIRECTOR 1.00 X 0 0 0 GORDON F TOMASELLI MD DIRECTOR 1.00 X 0 0 0 KEVIN J TRACEY MD DIRECTOR 1.00 X 0 0 0 ELIZABETH BROOKS O'BRIEN VP & GENERAL COUNSEL 40.00 X 440292 0 40576 THOMAS LEHNER SCI DIR, NEURO DIS GEN 40.00 X 362827 0 49280 SOREN GERMER SVP, GENOME TECHNOLOGIES 40.00 X 410837 0 34047 CAROL ASHE CHIEF BUSINESS OFFICER 40.00 X 405036 0 36117 CHARLES GAGNON SENIOR DIR, IT INFRASTRUCTURE 40.00 X 340516 0 46990 MARIA JOANTA CHIEF FIN. OFFICER (AS OF 7/21) 40.00 X 169606 0 19229 MICHAEL CHARLES ZODY SCIENTIFIC DIR, COMP BIOLOGY 40.00 X 277755 0 23134 KAREN L BUNTING SENIOR DIRECTOR, STRATEGIC INITIATIVES 40.00 X 226078 0 18686 SHAILAJA GARGEYA SENIOR DIR, SOFTWARE ENGINEER 40.00 X 318002 0 17787 DAYNA M OSCHWALD CHIEF OF STAFF 40.00 X 258478 0 31335 CHRISTOPHER PHIFER BLACK DIRECTOR, RESEARCH COMPUTING 40.00 X 218966 0 42403 NICOLAS ROBINE COMPUTATIONAL BIOLOGY 40.00 X 213550 0 37197 4886961 0 415048 75 0 1 0 DONNELLY MECHANICAL 96-59 222ND STREET QUEENS NY 11429 ENGINEERING SERVICES 720835 GUARDIAN SERVICES INDUSTRIES INC 88005 EXPEDITE WAY CHICAGO IL 60695 CLEANING SERVICES 353833 TEC SYSTEMS INC 47-25 34TH STREET 4TH FLOOR LONG ISLAND CITY NY 11101 MAINTENANCE SERVICES 177232 HOWSON & HOWSON LLP 5 SENTRY PKWY 160 BLUE BELL PA 19422 LEGAL SERVICES 134310 KPMG LLP PO BOX 120511 DALLAS TX 75312 ACCOUNTING SERVICES 130113 6 2735000 14510236 44311689 2724243 61556925 RESEARCH SEQUENCING 541700 7531190 5536740 1994450 CLINICAL SEQUENCING 541700 1471418 1471418 9002608 27107 27107 1251014 1251014 3674053 3471087 202966 202966 202966 OTHER MISC REVENUE 900099 258491 258491 258491 72299111 7008158 1994450 1739578 1593681 1593681 166389 166389 5255579 2109697 3002312 143570 185902 185902 16703387 13108257 3495018 100112 1123438 801984 306866 14588 2096930 1394563 687694 14673 2035272 1511007 503650 20615 235238 235238 127060 127060 50859 45859 5000 250 250 2558552 2306294 252258 314627 110256 203938 433 3110631 2836025 274606 395340 395340 14120934 11710583 2303138 107213 67457 66669 775 13 37508 28590 8486 432 268263 188575 76689 2999 5665542 5222851 405257 37434 660185 660185 DIRECT COST OF SEQUENCI 9496551 9496551 RESEARCH 2524924 2524924 RECRUITMENT 200665 49525 151140 OTHER 113257 25858 81182 6217 69108421 55833521 12821351 453549 9393791 10264308 4575195 7859130 4431588 6350857 1246622 2423898 3918628 3304280 133048124 85581035 51267221 47467089 8714187 7552563 83547232 85222125 6075510 5032047 11521530 12695217 71442 0 4820000 4100000 25106784 24252205 47595266 46079469 X 27915254 26513021 8036712 12629635 35951966 39142656 83547232 85222125 3190690 0 X 0 1 X 1 1 1 X 70723214 115038771 32878926 51639109 61556925 331836945 70723214 115038771 32878926 51639109 61556925 331836945 159305553 172531392 378725 2090669 3205975 3312682 4952174 13940225 95299 104653 38049 742082 258491 1238574 347015744 63775539 0.49720 0.54290 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 0 0 1 52638 52638 0 PART II-B, LINE 1: THROUGH ITS LEGISLATIVE CONSULTANTS, NYGC ADVOCATES AT THE STATE LEVEL FOR GOVERNMENT FUNDS TO SUPPORT CURRENT OPERATIONS AND/OR EXPAND RESEARCH OPPORTUNITIES AT NYGC. IN 2021, NYGC ENGAGED PAID LEGISLATIVE CONSULTANTS TO REPRESENT ITS INTERESTS AT THE STATE LEVEL. ADDITIONALLY, FROM TIME TO TIME, NYGC STAFF MAY CONTACT MEMBERS OF THE STATE LEGISLATURE AND EXECUTIVE BRANCH TO ENCOURAGE THEIR SUPPORT FOR NYGC. SUCH CONTACT MAY INCLUDE MEETINGS AND CORRESPONDENCE WITH PUBLIC OFFICIALS. THE APPROXIMATE COST ASSOCIATED WITH THESE ACTIVITIES IN 2021 WAS $23,377. NYGC ALSO MAINTAINS MEMBERSHIPS IN IRC SECTION 501(C)(6) ORGANIZATIONS THAT REPRESENT THE INTERESTS OF THE ACADEMIC MEDICAL RESEARCH COMMUNITY. IN 2021, $2,388 OF THE DUES THAT NYGC PAID TO THESE ASSOCIATIONS WERE ATTRIBUTABLE TO LOBBYING. 71059157 26565746 44493411 60492873 57519195 2973678 1496094 1496094 0 47467089 SECURITY DEPOSITS 7339122 DEFERRED COMPENSATION 213441 7552563 DEFERRED RENT 24252205 24252205 X 75770198 0 75770198 -3471087 -3471087 72299111 72579508 3471087 3471087 69108421 0 69108421 PART X, LINE 2: NYGC IS SUBJECT TO THE PROVISIONS OF THE FASB ASC SECTION 740-10-05, INCOME TAXES - OVERALL, RELATING TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. NYGC RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED AND HAS DETERMINED IT DID NOT HAVE ANY EXPOSURE TO UNCERTAIN TAX POSITIONS DURING 2021 AND 2020. PART XI, LINE 4B - OTHER ADJUSTMENTS: RENTAL EXPENSE -3,471,087. PART XII, LINE 2D - OTHER ADJUSTMENTS: RENTAL EXPENSE 3,471,087. 1 EUROPE (INCLUDING ICELAND AND GREENLAND) 14 PROGRAM SERVICES RESEARCH 480577 NORTH AMERICA 6 PROGRAM SERVICES RESEARCH 172931 MIDDLE EAST (NORTH AFRICA) 1 PROGRAM SERVICES RESEARCH 1808 EAST ASIA AND THE PACIFIC 1 PROGRAM SERVICES RESEARCH 499 EUROPE (INCLUDING ICELAND AND GREENLAND) 2 PROGRAM SERVICES RESEARCH SUBAWARD 166389 0 24 0 0 0 24 822204 0 822204 EUROPE (INCLUDING ICELAND AND GREENLAND) RESEARCH SUBAWARD 148514 WIRE 0 EUROPE (INCLUDING ICELAND AND GREENLAND) RESEARCH SUBAWARD 17875 WIRE 0 2 0 RESEARCH NORTH AMERICA 1 38779 WIRE 0 0 0 0 0 0 PART I, LINE 2: NYGC MONITORS THE USE OF GRANT FUNDS FOLLOWING THE UNIFORM GUIDANCE FOR FEDERAL AWARDS. GRANT RECIPIENTS ARE REQUIRED TO PROVIDE PROGRESS REPORTS. COSTS ARE REVIEWED FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES, BUDGETARY RESTRICTIONS, AND TERMS AND CONDITIONS OF THE AWARD BEFORE PAYMENT. PART I, LINE 3: THE PROGRAM EXPENDITURES ARE REPORTED ON THE ACCRUAL METHOD. PART III ACCOUNTING METHOD: 1 NEW YORK UNIVERSITY 105 E 17TH STREET NEW YORK NY 10003 135562308 501(C)(3) 440678 0 RESEARCH SUBAWARD COLD SPRING HARBOR LABORATORY ONE BUNGTOWN ROAD COLD SPRING HARBOR NY 11724 112013303 501(C)(3) 322523 0 RESEARCH SUBAWARD COLUMBIA UNIVERSITY 615 WEST 131ST STREET NEW YORK NY 10027 135598093 501(C)(3) 227755 0 RESEARCH SUBAWARD MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 110207 0 RESEARCH SUBAWARD THE BROAD INSTITUTE INC 415 MAIN STREET CAMBRIDGE MA 02142 263428781 501(C)(3) 71543 0 RESEARCH SUBAWARD ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501(C)(3) 51589 0 RESEARCH SUBAWARD UNIVERSITY OF WASHINGTON 129 SCHMITZ HALL 355870 SEATTLE WA 98195 916001537 WA 51281 0 RESEARCH SUBAWARD WEILL CORNELL MEDICAL COLLEGE 1300 YORK AVENUE NEW YORK NY 10065 150532082 501(C)(3) 27994 0 RESEARCH SUBAWARD YALE UNIVERSITY PO BOX 208356 NEW HAVEN CT 06520 060646973 501(C)(3) 15918 0 RESEARCH SUBAWARD WASHINGTON UNIVERSITY SCHOOL OF MEDICINE 700 ROSEDALE AVENUE CB 1034 ST LOUIS MO 63112 430653611 501(C)(3) 9113 0 RESEARCH SUBAWARD ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)(3) 7615 0 RESEARCH SUBAWARD JOHNS HOPKINS UNIVERSITY 3910 KESWICK ROAD BALTIMORE MD 21211 520595110 501(C)(3) 7063 0 RESEARCH SUBAWARD 12 0 PART I, LINE 2: NYGC MONITORS THE USE OF GRANT FUNDS FOLLOWING THE UNIFORM GUIDANCE FOR FEDERAL AWARDS. GRANT RECIPIENTS ARE REQUIRED TO PROVIDE PROGRESS REPORTS. COSTS ARE REVIEWED FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES, BUDGETARY RESTRICTIONS, AND TERMS AND CONDITIONS OF THE AWARD BEFORE PAYMENT. X 1 1 X X 0 0 0 0 0 0 0 0 0 CHERYL A MOORE PRESIDENT & COO (THROUGH 3/21) 256926 0 244600 0 127081 0 17400 0 867 0 646874 0 0 0 TOM MANIATIS PHD SCIENTIFIC DIRECTOR & CEO 612312 0 0 0 4099 0 0 0 0 0 616411 0 0 0 ELIZABETH BROOKS O'BRIEN VP & GENERAL COUNSEL 440292 0 0 0 0 0 17400 0 23176 0 480868 0 0 0 SOREN GERMER SVP, GENOME TECHNOLOGIES 410837 0 0 0 0 0 17400 0 16647 0 444884 0 0 0 CAROL ASHE CHIEF BUSINESS OFFICER 405036 0 0 0 0 0 36000 0 117 0 441153 0 18600 0 THOMAS LEHNER SCI DIR, NEURO DIS GEN 362827 0 0 0 0 0 36900 0 12380 0 412107 0 18101 0 CHARLES GAGNON SENIOR DIR, IT INFRASTRUCTURE 307096 0 29160 0 4260 0 17286 0 29704 0 387506 0 0 0 SHAILAJA GARGEYA SENIOR DIR, SOFTWARE ENGINEER 310998 0 7004 0 0 0 17400 0 387 0 335789 0 0 0 MICHAEL CHARLES ZODY SCIENTIFIC DIR, COMP BIOLOGY 277755 0 0 0 0 0 14344 0 8790 0 300889 0 0 0 DAYNA M OSCHWALD CHIEF OF STAFF 258478 0 0 0 0 0 14688 0 16647 0 289813 0 0 0 CHRISTOPHER PHIFER BLACK DIRECTOR, RESEARCH COMPUTING 218966 0 0 0 0 0 13648 0 28755 0 261369 0 0 0 NICOLAS ROBINE COMPUTATIONAL BIOLOGY 213550 0 0 0 0 0 13154 0 24043 0 250747 0 0 0 KAREN L BUNTING SENIOR DIRECTOR, STRATEGIC INITIATIV 226078 0 0 0 0 0 11394 0 7292 0 244764 0 0 0 MARIA JOANTA CHIEF FIN. OFFICER (AS OF 7/21) 169606 0 0 0 0 0 5550 0 13679 0 188835 0 0 0 PART I, LINE 1A HOUSING ALLOWANCE OR RESIDENCE FOR PERSONAL USE NYGC SELECTIVELY OFFERS HOUSING ALLOWANCES TO EMPLOYEES, PRINCIPALLY AS A RECRUITING TOOL FOR NEW FACULTY AND POSTDOCTORAL FELLOWS. SUBSIDIZED HOUSING OR HOUSING ALLOWANCES ARE COMMONLY OFFERED BY PEER ACADEMIC INSTITUTIONS IN NEW YORK CITY TO HELP FACULTY AND OTHER RESEARCHERS DEFRAY THE HIGH COST OF HOUSING. THE VALUE OF THIS ASSISTANCE WAS TREATED AS TAXABLE COMPENSATION TO THE EMPLOYEE. PART I, LINE 3 IN 2021, NYGC'S SCIENTIFIC DIRECTOR & CEO WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR & CEO, AN OFFICER OF THE CORPORATION AND AS A SENIOR ASSOCIATE MEMBER OF NYGC'S FACULTY. HE OVERSAW NYGC'S RESEARCH PROGRAM AND UNDERTOOK OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. THE SCIENTIFIC DIRECTOR & CEO DEVOTED 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS. IN JANUARY 2021, NYGC HIRED AN INDEPENDENT COMPENSATION CONSULTANT TO PERFORM AN EXECUTIVE TOTAL COMPENSATION STUDY OF SENIOR MANAGEMENT'S COMPENSATION, INCLUDING THE SCIENTIFIC DIRECTOR & CEO. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO ALL MEMBERS OF SENIOR MANAGEMENT, INCLUDING THE SCIENTIFIC DIRECTOR & CEO, WAS REASONABLE. SILAS MANIATIS FAMILY MEMBER 188095 SALARY+BENEFITS 0 X RESEARCH SUPPLIES 842 2724243 FMV 0 0 0 PART I, COLUMN (B): THE NUMBER REPORTED IN PART I, COLUMN B REPRESENTS THE NUMBER OF UNITS CONTRIBUTED. FORM 990, PART I, LINE 1 & PART III, LINE 1: THE NEW YORK GENOME CENTER (NYGC) IS AN INDEPENDENT, NONPROFIT MEDICAL RESEARCH ORGANIZATION THAT SERVES AS A MULTI-INSTITUTIONAL HUB FOR GENOMIC RESEARCH. LEVERAGING OUR STRENGTHS IN WHOLE-GENOME SEQUENCING AND GENOMIC ANALYSIS, OUR MISSION IS THE ADVANCEMENT OF GENOMIC SCIENCE AND ITS APPLICATION TO NOVEL BIOMEDICAL DISCOVERIES. NYGC'S AREAS OF FOCUS INCLUDE THE DEVELOPMENT OF NOVEL COMPUTATIONAL AND EXPERIMENTAL METHODS IN GENOMICS AND DISEASE-FOCUSED RESEARCH. THE CENTER IS KNOWN INTERNATIONALLY FOR ENHANCING OUR UNDERSTANDING OF THE GENETIC BASIS OF CANCER, NEURODEGENERATIVE DISEASE (ALS, ALZHEIMER'S, FTD, PARKINSON'S AND HUNTINGTON'S), AND NEUROPSYCHIATRIC DISEASE (AUTISM, SCHIZOPHRENIA, BIPOLAR DISORDER). SINCE 2020, THE NYGC HAS ALSO DIRECTED ITS EXPERTISE TO COVID-19 RESEARCH. NYGC SERVES AS A NEXUS FOR COLLABORATION IN GENOMIC RESEARCH FOR THE NEW YORK COMMUNITY AND BEYOND, BUILDING ON THE COMBINED STRENGTHS OF FACULTY, MEMBER INSTITUTIONS, SCIENTIFIC WORKING GROUPS, AFFILIATE MEMBERS, AND INDUSTRY PARTNERS. NYGC'S GROWTH AND DEDICATION TO EXCELLENCE EMPOWERS THE CLINICAL AND SCIENTIFIC COMMUNITY WITH THE RESOURCES AND EXPERTISE TO ACCELERATE GENOMIC SCIENCE. THE NYGC TEAM, LED BY EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO TOM MANIATIS, PHD, INCLUDES SENIOR AND CORE FACULTY MEMBERS WHO HOLD JOINT APPOINTMENTS AT LEADING ACADEMIC INSTITUTIONS. THE FACULTY INCLUDES A NOBEL LAUREATE, SIX NATIONAL ACADEMY OF SCIENCES MEMBERS, THREE LASKER AWARD WINNERS, THREE NIH NEW INNOVATOR AWARD WINNERS, THREE NIH PATHWAY TO INDEPENDENCE AWARD WINNERS, AS WELL AS ONE NIH DIRECTOR'S TRANSFORMATIVE RESEARCH AWARDEE. NYGC HAS 16 MEMBER INSTITUTIONS AND 85 AFFILIATED SCIENTISTS IN ADDITION TO ITS INTERNAL SCIENTIFIC TEAM, ROBUST RESEARCH PROGRAMS, STATE-OF-THE-ART, NEXT GENERATION SEQUENCING/ANALYTICS CAPABILITIES, A CLINICAL LABORATORY CERTIFIED BY THE NEW YORK STATE DEPARTMENT OF HEALTH, AND A CUTTING-EDGE TECHNOLOGY INNOVATION TEAM. WE CONSIDER THE EXCHANGE OF IDEAS AMONG RESEARCHERS, BOTH WITHIN AND OUTSIDE THE CENTER, TO BE ESSENTIAL FOR THE UNDERSTANDING OF THE GENETIC BASIS OF HUMAN DISEASES, DEVELOPMENT OF NEW GENOMIC TECHNOLOGIES, AND THE ADVANCEMENT OF BASIC SCIENCE. NYGC STRIVES TO CHAMPION DIVERSITY, EQUITY, AND INCLUSION. IN ADDITION TO THE WORKPLACE THIS INCLUDES RESEARCH AND IN ITS APPLICATION TO CLINICAL CARE. A FUNDAMENTAL GOAL OF THE GENOME CENTER IS ADDRESSING THE LACK OF DIVERSITY WITHIN DATA SAMPLES AND SUBJECTS IN GENOMICS RESEARCH. NYGC IS ALSO COMMITTED TO EXPANDING DIVERSITY AS REFLECTED WITHIN THE CENTER'S BOARD OF DIRECTORS AND WITHIN THE FACULTY, STAFF, AND SCIENTIFIC RESEARCHERS. FORM 990, PART III, LINE 4A & LINE 4B NYGC IS COMMITTED TO ITS MISSION OF ADVANCING GENOMIC SCIENCE AND ITS APPLICATION TO NOVEL BIOMEDICAL THERAPEUTICS AND ACCELERATE ITS USE IN THE CLINICAL SETTING. RESEARCH AND FACULTY --------------------- NYGC ATTRACTS WORLD-CLASS SCIENTISTS AND IS COMMITTED TO SUPPORTING EMERGING YOUNG FACULTY. NYGC RESEARCHERS HAVE BACKGROUNDS IN SINGLE CELL GENOMICS, GENOMIC ENGINEERING, EVOLUTIONARY GENOMICS, TECHNOLOGY AND METHODS DEVELOPMENT, COMPUTATIONAL BIOLOGY AND BIOENGINEERING. MOST FACULTY MEMBERS HAVE JOINT APPOINTMENTS AT ONE OF NYGC'S PARTNER INSTITUTIONS TO PROMOTE PRODUCTIVE COLLABORATION, STRENGTHEN RESEARCH, ADVANCE ACADEMIC LEADERSHIP, AND BETTER UNDERSTAND HOW TO TREAT HUMAN DISEASES. THIS YEAR, THE CENTER RECRUITED THREE HIGHLY SOUGHT-AFTER EARLY-STAGE INVESTIGATORS INCLUDING: DR. GAMZE GURSOY BEGAN HER INDEPENDENT RESEARCH CAREER AT NYGC WITH A JOINT APPOINTMENT IN THE COLUMBIA UNIVERSITY DEPARTMENTS OF BIOMEDICAL INFORMATICS AND COMPUTER SCIENCE. SHE BRINGS A DIVERSE BACKGROUND INCLUDING HER INTEREST IN DEVELOPING TOOLS TO ANALYZE AND UNDERSTAND THE RELATIONSHIP BETWEEN GENOMIC STRUCTURE, VARIATION, AND MOLECULAR PHENOTYPES ASSOCIATED WITH DISEASES AND ADDING PRIVACY-PRESERVATION TO THESE MODELS AND DATASETS TO ENABLE INFERENCE FROM SENSITIVE GENOTYPIC AND PHENOTYPIC DATA WHILE PRESERVING PATIENT PRIVACY. AS A POSTDOC, DR. GURSOY WAS AWARDED A HIGHLY COMPETITIVE AND PRESTIGIOUS NIH/K99 "PATHWAY TO INDEPENDENCE AWARD" IN 2020 FROM THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI). CHENXU ZHU, PHD, IS A "MULTIOMICS" RESEARCHER AND HIS LAB FOCUSES ON APPLYING AN ARRAY OF INNOVATIVE GENOMIC METHODS, INCLUDING SINGLE-CELL TECHNOLOGIES, TO BETTER UNDERSTAND GENE REGULATION MECHANISMS IN HUMAN DEVELOPMENT AND DISEASE, PARTICULARLY CANCER. HE JOINED NYGC FROM THE SAN DIEGO BRANCH OF THE LUDWIG INSTITUTE FOR CANCER RESEARCH, WHERE HE SERVED AS A POSTDOCTORAL FELLOW IN ITS LABORATORY OF GENE REGULATION. DR. ZHU OBTAINED HIS PHD IN BIOCHEMISTRY AND MOLECULAR BIOLOGY FROM PEKING UNIVERSITY. HE ALSO HOLDS A JOINT APPOINTMENT AS ASSISTANT PROFESSOR AT NYGC MEMBER INSTITUTION WEILL CORNELL MEDICINE (WCM) IN THE DEPARTMENT OF PHYSIOLOGY AND BIOPHYSICS AND INSTITUTE FOR COMPUTATIONAL BIOMEDICINE. SANJA VICKOVIC, PHD, JOINED NYGC AS A CORE FACULTY MEMBER AND DIRECTOR OF NYGC'S TECHNOLOGY INNOVATION LAB. DR. VICKOVIC WORKED AT THE BROAD INSTITUTE OF MIT AND HARVARD, WHERE SHE WAS A WALLENBERG FELLOW IN DR. AVIV REGEV'S LAB. SHE OBTAINED HER PHD IN GENE TECHNOLOGY FROM THE KTH ROYAL INSTITUTE OF TECHNOLOGY, STOCKHOLM. DR. VICKOVIC IS AN EXPERIENCED AND ACCOMPLISHED ENGINEER AND AN INVENTOR OF THE SPATIAL TRANSCRIPTOMIC TECHNOLOGY CALLED "VISIUM" NOW COMMERCIALIZED BY 10X GENOMICS. SHE ALSO HAS TRAINING AND EXPERIENCE IN MATHEMATICS AND BIOLOGICAL SCIENCES. DR. VICKOVIC CURRENTLY HOLDS MULTIPLE JOINT APPOINTMENTS WHILE AT NYGC. SHE IS AN ASSISTANT PROFESSOR AT THE FU FOUNDATION SCHOOL OF ENGINEERING AND APPLIED SCIENCE AND THE HERBERT AND FLORENCE IRVING INSTITUTE FOR CANCER DYNAMICS AT COLUMBIA UNIVERSITY, AS WELL AS REMAINING A WALLENBERG ACADEMY FELLOW OF THE ROYAL SWEDISH ACADEMY OF SCIENCES AND THE ROYAL SWEDISH ACADEMY OF ENGINEERING SCIENCES AT UPPSALA UNIVERSITY. IN 2021, NYGC SCIENTISTS RECEIVED PRESTIGIOUS AWARDS FOR THEIR CONTRIBUTIONS TO PIONEERING RESEARCH, RELEASED FINDINGS FROM NEW STUDIES, AND DEVELOPED NEW GENOMIC TOOLS AND TECHNOLOGIES TO HELP ADVANCE PRECISION MEDICINE: DAN LANDAU, MD, PHD, RECEIVED A 2021 TOP 10 CLINICAL RESEARCH ACHIEVEMENT AWARD FOR HIS LAB'S BREAKTHROUGH TRANSLATIONAL RESEARCH IN DEVELOPING A HIGHLY SENSITIVE "LIQUID BIOPSY" BLOOD TEST FOR MONITORING OF CANCER PROGRESSION AND RELAPSE. DR. LANDAU ALSO LED THE TEAM THAT DEVELOPED A NEW MACHINE LEARNING TECHNIQUE THAT ANALYZES THE THOUSANDS OF DNA METHYLATION CHANGES DETECTED IN TUMOR CELLS -- AND INFERS WHICH ONES ARE LIKELY TO DRIVE TUMOR GROWTH. MARCIN IMIELINSKI, MD, PHD, IS AN AWARDEE OF THE 2021 PERSHING SQUARE SOHN PRIZE FOR YOUNG INVESTIGATORS IN CANCER RESEARCH. THE AWARD IS TO SUPPORT HIS PROJECT TO EXPLAIN WHY CERTAIN ACRAL MELANOMAS (WHICH OCCUR ON THE HANDS AND FEET) AND OTHER SIMILAR CANCERS WITH FEW SMALL MUTATIONS RESPOND TO IMMUNOTHERAPY BY EXAMINING A NOVEL CLASS OF GENETIC ALTERATIONS CALLED TYFONAS. THIS STUDY CAN TRANSFORM THE BASIC UNDERSTANDING OF CANCER EVOLUTION AND PROVIDE EVIDENCE FOR A WHOLE GENOME SEQUENCING IMMUNOTHERAPY BIOMARKER TO HELP NAVIGATE THE BEST COURSE FOR PATIENT TREATMENT. DR. IMIELINSKI ALSO LED THE MULTI-INSTITUTIONAL CANCER GENOMICS RESEARCH TEAM THAT RELEASED FINDINGS FROM A COMPREHENSIVE WHOLE-GENOME SEQUENCING STUDY OF A KEY SUBSET OF LUNG ADENOCARCINOMA (LUAD). THE TEAM'S REPORT DETAILS THEIR UNCOVERING OF STRUCTURAL GENETIC VARIANTS THAT MAY BE POTENTIAL NEW BIOMARKERS AND THERAPEUTIC TARGETS FOR LUAD, THE MOST COMMON LUNG MALIGNANCY AND A LEADING CAUSE OF CANCER DEATH IN THE U.S. RAHUL SATIJA, PHD, LED THE TEAM THAT DEVELOPED MIXSCAPE, A NEW COMPUTATIONAL TOOL TO INTERPRET EXPERIMENTS THAT COMBINE THE USE OF CRISPR TO PERTURB GENES ALONG WITH MULTIMODAL SINGLE-CELL SEQUENCING TECHNOLOGIES. THIS NEW TOOL HELPED TO IDENTIFY A NEW MOLECULAR MECHANISM FOR THE REGULATION OF IMMUNE CHECKPOINT PROTEINS THAT GOVERN THE IMMUNE SYSTEM'S ABILITY TO IDENTIFY AND DESTROY CANCER CELLS. NEVILLE SANJANA, PHD, RECEIVED A 2021 GRANT FROM THE SIMONS FOUNDATION (SFARI) TO SUPPORTS A PROJECT TO DEPLOY CRISPR AND OTHER TECHNOLOGIES TO UNCOVER BIOMARKERS FOR AUTISM GENE THERAPY. HEMALI PHATNANI, PHD IS A 2021 RECIPIENT OF THE NIH DIRECTOR'S TRANSFORMATIVE RESEARCH AWARD, PART OF THE NIH'S HIGH-RISK, HIGH-REWARD PROGRAM TO PROMOTE EXCEPTIONALLY INNOVATIVE OR UNCONVENTIONAL RESEARCH PROJECTS WITH THE POTENTIAL TO CREATE OR OVERTURN FUNDAMENTAL PARADIGMS. DR. PHATAMI WAS ALSO AWARDED A DEFENSE DEPT GRANT TO STUDY ALS-FRONTOTEMPORAL DEMENTIA. ADDITIONAL ACCOMPLISHMENTS IN 2021 INCLUDE: OVER THE PAST YEAR, NYGC HAS MADE GREAT PROGRESS IN CORE RESEARCH AREAS UNDER THE LEADERSHIP OF THE NEW YORK GENOME CENTER'S EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO, TOM MANIATIS. IN 2021, DR. MANIATIS WAS NAMED TO NEW YORK'S FIRST "CITY & STATE LIFE SCIENCES POWER 50" LIST, HIGHLIGHTING KEY INDIVIDUALS DRIVING THE LIFE SCIENCE SECTOR'S GROWTH IN NEW YORK. NYGC FACULTY PUBLISHED OVER 75 STUDIES IN HIGH-IMPACT SCIENTIFIC JOURNALS THAT PROVIDED NEW INSIGHTS INTO DISEASE MECHANISMS. NYGC RESEARCHERS HAVE DEVELOPED MANY INNOVATIVE GENOMIC TECHNOLOGIES AND NEW COMPUTATIONAL APPROACHES THAT ARE SHARED WIDELY WITH THE SCIENTIFIC COMMUNITY. CANCER: THE GENOME CENTER CANCER GROUP (GCCG), LED BY HAROLD VARMUS, MD, NYGC AND WEILL CORNELL MEDICINE, AND CHARLES SAWYERS, MD, MEMORIAL SLOAN KETTERING CANCER CENTER, IS COMPOSED OF CLINICIANS AND CANCER RESEARCHERS FROM NYGC'S MEMBER INSTITUTIONS, INCLUDING 10 NCI-DESIGNATED CANCER CENTERS. NYGC'S COLLABORATIVE CANCER INITIATIVE, POLYETHNIC-1000 (P-1000), WAS LAUNCHED IN 2018 TO ADVANCE CANCER GENOMICS IN UNDERREPRESENTED POPULATIONS. IN THE PAST YEAR, THE PROGRAM HAS APPOINTED TWO DISTINGUISHED CANCER AND ETHNICITY SCHOLARS, ONYINYE BALOGUN, MD, AND MELISSA B. DAVIS, PHD, ESTEEMED HEALTH DISPARITIES RESEARCHERS AT WEILL CORNELL MEDICINE WHO PROVIDE OVERSIGHT OF THE CONDUCT AND COORDINATION OF P-1000'S NEXT PHASE OF RESEARCH ACTIVITIES. DR. DAVIS RECENTLY AUTHORED A "SCIENCE & SOCIETY" ESSAY IN TRENDS IN CANCER. ADDITIONALLY, THE VERY RARE CANCER CONSORTIUM (VRCC) IS A RESEARCH COHORT FOCUSED ON UNDERSTANDING THE GENETIC CAUSES OF RARE, UNDERSTUDIED CANCERS AND LEVERAGES THE COMBINED EXPERTISE FROM INSTITUTIONS ACROSS NEW YORK CITY. THROUGH A NETWORK OF 20 MEMBER INSTITUTIONS, THIS PROJECT AIMS TO COLLECT SAMPLES OF VERY RARE CANCERS IN SUFFICIENT NUMBERS TO PROVIDE ANSWERS TO IMPORTANT SCIENTIFIC QUESTIONS, BUILD RESEARCH COHORTS, AND REDUCE THE TOLL TAKEN BY UNDERSTUDIED DISEASES. NEURODEGENERATIVE DISEASE: HEMALI PHATNANI, PHD, CORE FACULTY MEMBER AND DIRECTOR OF THE CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE AT NYGC, CONVENED THE THIRD NYGC ALS CONSORTIUM BIANNUAL MEETING IN WHICH ONE HUNDRED RESEARCHERS AND CLINICIANS, FROM 40+ GLOBAL MEMBER INSTITUTIONS, SHARED THE LATEST IN ALS GENOMICS RESEARCH AND CELEBRATED MILESTONE ACCOMPLISHMENTS INCLUDING CREATING ONE OF THE LARGEST ALS DATA COHORTS IN THE WORLD, EMPOWERING AN INTEGRATED GLOBAL APPROACH TO ADVANCE NEW TREATMENTS AND EFFECTIVE THERAPIES FOR THIS COMPLEX DISEASE. FORM 990, PART III, LINE 4A NEUROPSYCHIATRIC DISEASE: DR. THOMAS LEHNER, NYGC'S SCIENTIFIC DIRECTOR FOR NEUROPSYCHIATRIC DISEASE, LEADS NYGC'S NEUROPSYCHIATRIC DISEASE SCIENTIFIC WORKING GROUP. A KEY PROJECT THE GROUP IS DEVELOPING IS GEMMA (GENOMIC MEDICINE FOR MENTAL HEALTH AVANCEMENT). GEMMA IS A NEW YORK STATE-WIDE PRECISION PSYCHIATRY PLATFORM THAT INTEGRATES DIAGNOSTIC, DEMOGRAPHIC, AND PATIENT CARE DATA WITH GENOMIC DATA AND OTHER MEDICAL RECORDS FOR SCIENTIFIC DISCOVERY, CLINICAL VALIDATION, AND TRANSLATIONAL IMPLEMENTATION. THIS UNPRECEDENTED RESOURCE WOULD RAPIDLY DEEPEN THE KNOWLEDGE BASE OF DIVERSE BIOMARKERS AND GENETIC FACTORS DRIVING NEUROPSYCHIATRIC DISEASE ENABLING A TRANSFORMATIVE EXPANSION OF THE PREDICTIVE AND DIAGNOSTIC VALUE OF GENOMIC TESTS, CLINICALLY ACTIONABLE FINDINGS, THERAPEUTIC DEVELOPMENT, AND PERSONALIZED TREATMENT GUIDELINES BASED ON INDIVIDUAL GENETIC MAKEUP AND MACHINE LEARNING-BASED DATA MINING WHICH WILL VASTLY IMPROVE PATIENT EXPERIENCE AND OUTCOMES. NYGC CHIEF DIAGNOSTIC OFFICER VAIDEHI JOBANPUTRA, PHD, FACMG, IS A MEMBER OF THE INVESTIGATIVE TEAM THAT CONDUCTED WHOLE GENOME SEQUENCING ANALYSIS OF 200+ FAMILIES THAT INCLUDED INDIVIDUALS WITH SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS. BASED ON THEIR ANALYSIS, THE TEAM IDENTIFIED MORE FINELY TARGETED DIAGNOSES FOR MANY OF THESE INDIVIDUALS, AS WELL AS UNCOVERED BIOMARKERS REGARDING TOLERANCE/RESISTANCE TO ANTIPSYCHOTIC TREATMENTS. THE TEAM NOTES THAT WHOLE GENOME SEQUENCING CAN PLAY A POWERFUL ROLE IN THE SETTING OF BOTH RESEARCH AND GENETIC COUNSELING FOR INDIVIDUALS WITH SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS AND THEIR FAMILIES. THE STUDY, DRAWING FROM PARTICIPANTS AROUND THE GLOBE, WAS PUBLISHED IN MOLECULAR PSYCHIATRY IN 2021. COVID-19: IN 2020, NYGC ESTABLISHED THE COVID-19 GENOMICS RESEARCH NETWORK (CGRN), A MULTIDISCIPLINARY CONSORTIUM TO SUPPORT GLOBAL COVID-19 GENOMICS RESEARCH COLLABORATION AND BUILD AN INFORMATION-SHARING DATABASE. THIS RESOURCE HELPS SUPPORT THE ONGOING EFFORTS TO IMPROVE THE TREATMENT OF PATIENTS AND BETTER UNDERSTAND THE EVOLUTION OF THE VIRUS, AS WELL AS THE LONG-TERM IMPACT ON POPULATION HEALTH. ADDITIONALLY, NYGC'S CLINICAL LABORATORY CONDUCTED COVID-19 TESTING FOR VARIOUS HEALTHCARE ENTITIES AND THE RESEARCH STAFF CONTRIBUTED TO VIRAL SURVEILLANCE EFFORTS THROUGHOUT NEW YORK AND NEW JERSEY WITH THE GOAL OF IDENTIFYING NEW VIRAL VARIANTS THAT INCREASE THE SPREAD OF THE PATHOGEN. THESE EFFORTS RESULTED IN SEVERAL PUBLICATIONS. CLINICAL LABORATORY: NYGC'S CLINICAL LABORATORY HAS LENT ITS INFRASTRUCTURE AND EXPERTISE TO SEVERAL LARGE INITIATIVES IN CLINICAL GENOMICS, INCLUDING PARTNERING WITH ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI LED NYCKIDSEQ PROJECT AS PART OF THE NHGRI, NCI, AND NIMHD FUNDED CLINICAL SEQUENCING EVIDENCE-GENERATING RESEARCH (CSER) CONSORTIUM. THIS EFFORT PRIORITIZES GENOME SEQUENCING OF HISTORICALLY UNDERREPRESENTED PATIENT POPULATIONS TO IMPROVE CLINICAL OUTCOMES AND STUDY THE EFFECTIVENESS OF INTEGRATING GENOME SEQUENCING INTO CLINICAL CARE AND DEVELOP BEST PRACTICES FOR DISCOVERY, INTERPRETATION, RETURN OF RESULTS, AND HEALTHCARE UTILIZATION. IN ADDITION, THE NYGC CLINICAL LABORATORY IS CURRENTLY COLLABORATING WITH WEILL CORNELL MEDICINE, NEWYORK-PRESBYTERIAN HOSPITAL, AND ILLUMINA ON A PRECISION MEDICINE COLLABORATION IN CANCER, CARDIOLOGY, ENDOCRINOLOGY, AND NEUROLOGY TO ASSESS AND IMPROVE THE VALUE OF CLINICAL WHOLE GENOMES WITH AIMS OF RETURNING CLINICALLY ACTIONABLE RESULTS, INTEGRATING ELECTRONIC HEALTH RECORDS, DEVELOPING NOVEL POLYGENIC RISK SCORES, AND UNDERSTANDING THE ROLE OF GENETICS IN THERAPEUTIC RESPONSES. RESEARCH SEQUENCING ------------------- NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST SIX YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED OVER 82,000 WHOLE GENOME SAMPLES. NYGC HAS FIVE NOVASEQ SYSTEMS SEQUENCERS, WITH THE CAPACITY TO SEQUENCE THOUSANDS OF GENOMES A YEAR. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. NYGC'S RESEARCH SEQUENCING LAB, LED BY SOREN GERMER, PHD, SENIOR VICE PRESIDENT OF GENOME TECHNOLOGIES, PROCESSED MORE THAN 14,000 SAMPLES IN 2021, INCLUDING 4,552 WHOLE GENOME SEQUENCING SAMPLES (GERMLINE AND CANCER), 5,787 COVID VIRAL SAMPLES, 3,341 TRANSCRIPTOME (RNA) SEQUENCING SAMPLES. IN 2021 THE PRODUCTION SEQUENCING LAB WAS AWARDED NEW CONTRACTS FROM NHLBI FOR A TOTAL OF UP TO $5,640,230. NYGC ALSO PURCHASED TWO NEW SEQUENCING INSTRUMENTS IN 2021; ONE INSTRUMENT ADDS LONG READ CAPACITY TO THE CENTER'S SEQUENCING MENU, THE OTHER PROMISES SUBSTANTIALLY REDUCED REAGENT COSTS FOR HIGH-THROUGHPUT APPLICATIONS AND HAS CREATED A LOT OF EXCITEMENT IN THE GENOMICS COMMUNITY. AS ONE OF THE FEW EARLY ADOPTERS OF THIS TECHNOLOGY, NYGC IS WORKING INTENSIVELY TO ENABLE THIS TECHNOLOGY FOR A RANGE OF APPLICATIONS. IN 2021, NYGC CONTINUED TO EXPAND ITS OPERATIONAL FOCUS ON SINGLE-CELL GENOMICS, MAKING AVAILABLE TO THE RESEARCH COMMUNITY THROUGH FUNCTIONAL GENOMIC COLLABORATIONS NEW CUTTING-EDGE TECHNIQUES INVENTED IN THE CENTER'S INNOVATION LAB. THESE INCLUDE CITE-SEQ, ASAP-SEQ, DOGMA-SEQ AS WELL AS THE 10X MULTIOME ASSAY, TECHNIQUES THAT ALLOW SIMULTANEOUS MEASUREMENT IN THOUSANDS OF CELLS COMBINATIONS OF CELL SURFACE PROTEIN MARKERS, RNA ABUNDANCE AND CHROMATIN ACCESSIBILITY. THE CENTER'S TECHNOLOGY INNOVATION LABORATORY HAS COMPLETED SEVERAL PROJECTS AND IS GEARING UP TO SUPPORT MULTIPLE LARGE GRANTS IN WHICH THESE ASSAYS WILL BE APPLIED. IN ADDITION, THE LAB HAS IMPLEMENTED A NOVEL AMPLIFICATION FREE SINGLE CELL WHOLE GENOME SEQUENCING ASSAY THAT IS BEING USED IN A LARGE STUDY OF ESOPHAGEAL CANCER IN A COLLABORATION WITH COLUMBIA UNIVERSITY AND CAMBRIDGE UNIVERSITY. FORM 990, PART III, LINE 4A DIVERSITY, EQUITY, AND INCLUSION --------------------- IN 2020, NYGC LAUNCHED AN ORGANIZATION-WIDE DIVERSITY, EQUITY, AND INCLUSION INITIATIVE, AFFIRMING NYGC'S COMMITMENT TO TAKE ACTIONABLE STEPS TOWARD CREATING A COMMUNITY ENVIRONMENT THAT IS WELCOMING AND INCLUSIVE TO ALL REGARDLESS OF RACE, ETHNICITY, GENDER, SEXUAL ORIENTATION, PHYSICAL ABILITY, AGE, OR RELIGION. IN 2021, NYGC'S CROSS-FUNCTIONAL DIVERSITY, EQUITY AND INCLUSION (DEI) ADVISORY GROUP, WHOSE GOAL IS TO FOSTER AND PROMOTE DIVERSITY, EQUITY AND INCLUSION THROUGHOUT ALL ASPECTS OF NYGC'S WORK AND CULTURE, PROVIDED EDUCATION AND RESOURCES TO THE NYGC COMMUNITY TO RAISE AWARENESS OF INEQUALITY AND BIAS AND TO ENHANCE CULTURAL COMPETENCY. EXAMPLES INCLUDE BOOK CLUBS, ORGANIZATION-WIDE TRAINING ON ISSUES RELATED TO DIVERSITY AND INCLUSION, AND THE DEVELOPMENT OF A WORKPLACE CULTURE SURVEY. THE GROUP, IN CLOSE PARTNERSHIP WITH NYGC'S SENIOR TEAM, HAS SHOWCASED THE WORK AND SKILLS OF DIVERSE EMPLOYEES, STAFF, FACULTY AND TRAINEES, WITH MENTORSHIP CAREER PANELS, AND BY DEVELOPING WEB PAGES, ARTICLES AND COMMUNICATIONS ON DEI-RELATED TOPICS. IT IS ALSO WORKING TO PROMOTE AND SUPPORT AN INCLUSIVE RESEARCH AND TRAINING ENVIRONMENT, INCLUDING BY HOSTING AN INTERNSHIP PROGRAM FOR UNDER-REPRESENTED MINORITIES IN 2021. NYGC IS COMMITTED TO ADDRESSING SYSTEMIC RACISM AND INEQUALITIES IN SCIENCE AND IN THE WORKPLACE AND WILL CONTINUE TO EXPAND ITS WORK IN ALL OF THESE AREAS. FORM 990, PART VI, SECTION A, LINE 6 AS OF DECEMBER 31, 2021, THE CENTER HAD A TOTAL OF 20 MEMBERS, CONSISTING OF 12 INSTITUTIONAL FOUNDING MEMBERS AND EIGHT ASSOCIATE MEMBERS. *THE INSTITUTIONAL FOUNDING MEMBERS ARE THE FOLLOWING RECOGNIZED ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS: (1) COLD SPRING HARBOR LABORATORY, (2) CORNELL UNIVERSITY/WEILL CORNELL MEDICINE, (3) THE JACKSON LABORATORY, (4) MEMORIAL SLOAN-KETTERING CANCER CENTER, (5) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, (6) NEW YORK-PRESBYTERIAN HOSPITAL, (7) NEW YORK UNIVERSITY, SCHOOL OF MEDICINE, (8) NORTHWELL HEALTH, (9) THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, ON BEHALF OF STONY BROOK UNIVERSITY, (10) THE ROCKEFELLER UNIVERSITY, (11) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, AND (12) ALBERT EINSTEIN COLLEGE OF MEDICINE. *ASSOCIATE MEMBERS: (1) AMERICAN MUSEUM OF NATURAL HISTORY, (2) HOSPITAL FOR SPECIAL SURGERY, (3) THE NEW YORK STEM CELL FOUNDATION, (4) ROSWELL PARK CANCER INSTITUTE, (5) PRINCETON UNIVERSITY, (6) HACKENSACK MERIDIAN HEALTH, (7) GEORGETOWN LOMBARDI COMPREHENSIVE CANCER CENTER, AND (8) RUTGERS CANCER INSTITUTE OF NEW JERSEY. FORM 990, PART VI, SECTION A, LINE 7A EACH INSTITUTIONAL FOUNDING MEMBER APPOINTS ONE REPRESENTATIVE TO SERVE ON NYGC'S BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES THE SCIENTIFIC DIRECTOR AND OTHER DESIGNATED DIRECTORS OR INDIVIDUALS APPOINTED BY THE BOARD. DECISIONS REQUIRING BOARD APPROVAL INCLUDE THE ADMISSION OF NEW MEMBERS, CHANGES TO THE MISSION, CERTIFICATE OF INCORPORATION, AND BYLAWS, APPOINTMENT OR REMOVAL OF THE CHAIRPERSON OF THE BOARD AND THE SCIENTIFIC DIRECTOR, AND ADOPTION OF CERTAIN POLICIES AND PROCEDURES. THE BOARD ALSO REVIEWS AND APPROVES THE ANNUAL OPERATING BUDGET. MANAGEMENT HAS THE ABILITY TO ENTER INTO BUSINESS ARRANGEMENTS AND CONTRACTS, INCLUDING FINANCING ARRANGEMENTS AND HAS THE DISCRETION TO MAKE CERTAIN DECISIONS WITHOUT FORMAL BOARD APPROVAL. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY AN INDEPENDENT PUBLIC ACCOUNTING FIRM, UTILIZING INFORMATION PROVIDED BY MANAGEMENT. UPON RECEIPT OF THE DRAFT FORM 990, MANAGEMENT, INCLUDING THE CHIEF FINANCIAL OFFICER; DIRECTOR OF FINANCE; GENERAL COUNSEL; AND THE SCIENTIFIC DIRECTOR/CEO REVIEW THE FORM. PRIOR TO FILING, MANAGEMENT PRESENTS THE FORM 990 TO THE AUDIT COMMITTEE OF THE BOARD FOR REVIEW AND COMMENT. ALSO PRIOR TO FILING, MANAGEMENT PROVIDES THE FORM 990 TO THE ENTIRE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C NYGC REQUIRES ALL INTERESTED PERSONS (DEFINED AS BOARD MEMBERS, OFFICERS, AND KEY EMPLOYEES) TO DISCLOSE CONFLICTS OF INTEREST AS REQUIRED BY THE CONFLICT OF INTEREST POLICY. NYGC FOLLOWS A PROCEDURE FOR OBTAINING SUCH DISCLOSURES ANNUALLY. ANY POTENTIAL CONFLICTS OF INTEREST DISCLOSED BY BOARD MEMBERS OR OFFICERS MUST BE REVIEWED BY THE BOARD. IF AN INTERESTED PERSON HAS A POTENTIAL CONFLICT OF INTEREST, HE OR SHE MAY PRESENT INFORMATION RELEVANT TO THE CONFLICT OF INTEREST OR UNDERLYING TRANSACTION AT A BOARD OR COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE TRANSACTION OR ARRANGEMENT THAT CREATES THE POTENTIAL CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 FOR THE ORGANIZATION'S TOP MANAGEMENT OFFICIAL, PLEASE REFER TO SCHEDULE J NARRATIVES FOR THE PROCESS OF DETERMINING COMPENSATION. FOR 2021, NYGC HIRED AN INDEPENDENT, OUTSIDE COMPENSATION CONSULTANT TO PERFORM AN ANALYSIS OF SENIOR MANAGEMENT'S TOTAL COMPENSATION. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO MEMBERS OF SENIOR MANAGEMENT (CHERYL MOORE, CAROL ASHE, SOREN GERMER, ELIZABETH O'BRIEN, MICHAEL ZODY, THOMAS LEHNER AND TOM MANIATIS) WAS REASONABLE. THE AD-HOC COMPENSATION COMMITTEE OF THE BOARD (WHICH IS COMPOSED OF INDEPENDENT BOARD MEMBERS) MET WITH THE OUTSIDE CONSULTANT AT A COMMITTEE MEETING HELD IN JANUARY 2021 AND APPROVED THE 2021 COMPENSATION TO BE PAID TO SENIOR MANAGEMENT. THE COMMITTEE DOCUMENTED ITS ACTIONS IN WRITTEN MEETING MINUTES. IN MID-2021, ACTING ON INFORMATION PROVIDED BY NYGC'S INDEPENDENT COMPENSATION CONSULTANT, NYGC INCREASED MICHAEL ZODY'S SALARY TO BRING IT CLOSER TO MARKET LEVELS. THIS SALARY CHANGE WAS REVIEWED AND APPROVED BY THE AD-HOC COMPENSATION COMMITTEE OF THE BOARD AND DOCUMENTED IN WRITING. IN MID-2021, CHARLES GAGNON WAS PROMOTED TO THE EXECUTIVE ROLE OF CHIEF INFORMATION OFFICER AND GIVEN A SALARY INCREASE. PRIOR TO HIS PROMOTION, NYGC OBTAINED AN INDEPENDENT COMPENSATION ANALYSIS FOR THE POSITION, CONFIRMING THAT HIS PROPOSED SALARY INCREASE WAS REASONABLE. THE INDEPENDENT COMPENSATION ANALYSIS WAS REVIEWED BY THE AD-HOC COMPENSATION COMMITTEE OF THE BOARD, WHICH APPROVED MR. GAGNON'S SALARY AND DOCUMENTED ITS DECISION IN WRITING. IN OCTOBER 2021, SARAH LESSER AVINS WAS HIRED INTO THE EXECUTIVE ROLE OF SENIOR VICE PRESIDENT, ADVANCEMENT. PRIOR TO MS. AVINS HIRE, NYGC OBTAINED AN INDEPENDENT COMPENSATION ANALYSIS FOR THE POSITION CONFIRMING THAT HER PROPOSED TOTAL COMPENSATION WAS REASONABLE. THE INDEPENDENT COMPENSATION ANALYSIS WAS REVIEWED BY THE AD-HOC COMPENSATION COMMITTEE OF THE BOARD, WHICH APPROVED MS. AVINS COMPENSATION AND DOCUMENTED ITS DECISION IN WRITING. THE SENIOR MANAGEMENT TEAM RECEIVED STANDARD MERIT INCREASES IN 2021. FORM 990, PART VI, SECTION C, LINE 19 NYGC'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART VII, SECTION A IN 2021, TOM MANIATIS, PHD., SCIENTIFIC DIRECTOR & CEO, WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR AND CEO, AN OFFICER OF THE CORPORATION, AND AN ASSOCIATE MEMBER OF NYGC'S FACULTY, WITH RESPONSIBILITY FOR OVERSEEING NYGC'S RESEARCH PROGRAMS AND FOR UNDERTAKING SUCH OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. DR. MANIATIS DEVOTES 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS.